Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds.
Ninety analogues of suramin have been examined for their ability to inhibit the exogenous reverse transcriptase (RT) of human immunodeficiency virus type I (HIV-I). Of these compounds, 57 inhibited the poly(rC).oligo(dG)-dependent RT activity. Three classes of dose-response curves could be discriminated. Allocation of a compound to one class did not correspond with obvious structural features. Twenty-four substances were superior to suramin in our RT inhibition assay. The RT-inhibitory activity of these compounds did not correlate with their effect against filariae or trypanosomes. Preliminary antiviral evaluation in susceptible human T cells inoculated with HIV-I demonstrated in vitro therapeutic efficacy for some compounds with lower drug-related cellular toxicity than suramin. Certain structural features relevant for the RT-inhibitory effect of these compounds were recognized. Predictions are made for the design of more effective RT inhibitors. Such compounds will help to understand the molecular mechanism of reverse transcription and might be useful in the therapy of retroviral infections.
D002460:Cell Line; D017977:Deltaretrovirus / Q000201:enzymology*; D007700:Kinetics; D018894:Reverse Transcriptase Inhibitors; D013329:Structure-Activity Relationship; D013498:Suramin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*
D018894:Reverse Transcriptase Inhibitors; D013498:Suramin